Trial Profile
A randomized multicenter phase III study of taxane/carboplatin/cetuximab versus taxane/carboplatin as first-line treatment for patients with advanced/metastatic non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2019
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Docetaxel; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 25 Jan 2010 Results published in the Journal of Clinical Oncology.
- 06 Nov 2008 Status changed from active, no longer recruiting to completed.
- 30 Aug 2008 Primary endpoint 'Survival' has not been met.